Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock

Bibliography

• STONE R: Search for sepsis drugs goes on despite past failures. Science (1994) 264:365–367.
   PubMed Web of Science ®Google Scholar
• BURRELL R: Human responses to bacterial endotoxin. Circ. Shock (1994) 43:137–153.
   PubMedGoogle Scholar
• •Studies where healthy humans have received endotoxin are reviewed.
   Google Scholar
• SUFFREDINI AF, FROMM RE, PARKER MM et al: The cardiovascular response of normal humans to the administration of endotoxin. N Engl. J. Med. (1989) 321:280–287.
   PubMed Web of Science ®Google Scholar
• FREUDENBERG MA, GALANOS C: Bacterial lipopolysac-charides: structure, metabolism and mechanisms of action. Int. Rev. Immunol. (1990) 6:207–221.
   PubMedGoogle Scholar
• DAHINDEN C, GALANOS C, FEHR J: Granulocyte activa-tion by endotoxin. I. Correlation between adherence and other granulocyte functions and role of endotoxin structure on biologic activity. J. Immunol (1983) 130:857–862.
   Google Scholar
• GRISHAM. MB, EVERSE J, JANSSEN HF: Endotoxemia andneutrophil activation in vivo. Am. J. Physiol. (1988) 2:H1017–H1022.
   Google Scholar
• MURAKAMI K, OKAJIMA K, UCHIBA M et al.: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood (1996) 87:642–647.
   PubMed Web of Science ®Google Scholar
• BASU S: Radioimmunuassay of 8-iso-prostaglandinF2a: an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leuko. Essent. Fatty Acids (1998) 58:319–325.
   PubMed Web of Science ®Google Scholar
• BASU S: Radioimmunoassay of 15-keto-13,14-dihydro-prostaglandin F2alpha: an index for inflammation via cyclooxygenase catalysed lipid peroxidation. Prosta-glandins Leuko. Essent. Fat Oi Acids (1998) 58:347–352.
   PubMed Web of Science ®Google Scholar
• BASU S, ERIKSSON M: Oxidative injury and survival during endotoxemia. FEBS Lett. (1998) 438:159–160.
   PubMed Web of Science ®Google Scholar
• BASU S, ERIKSSON M: Lipid peroxidation induced by an early inflammatory response in endotoxaemia. Acta Anaesthesiol. Scand. (2000) 44:17–23.
   PubMed Web of Science ®Google Scholar
• •Increased lipid peroxidation is associated with endotox-aemic organ dysfunction and mortality.
   Google Scholar
• MODIG J: Adult respiratory distress syndrome. Comp. Pathol. Bull. (1989) 21:2–4.
   Google Scholar
• CIRINO G, CICALA C, BUCCI MR, SORRENTINO L, MARAGANORE JM, STONE SR: Thrombin functions as an inflammatory mediator through activation of its receptor. J. Exp. Med. (1996) 183:821–827.
   PubMed Web of Science ®Google Scholar
• COLOTTA F, SCIACCA FL, SIRONI M, LUINI W, RABIET MJ, MANTOVANI A: Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am. J. Pathol. (1994) 144:975–985.
   PubMed Web of Science ®Google Scholar
• MARKWARDT F, NOWAK G, STURZEBECHER J: Clinicalpharmacology of recombinant hirudin. Haemostasis (1991) 1:133–136.
   Google Scholar
• NOWAK G, MARKWARDT F: Hirudin in disseminatedintravascular coagulation. Haemostasis (1991) 1:142–148.
   Google Scholar
• CICALA C, BUCCI MR, MARAGANORE JM, CIRINO G: Hirulog effect in rat endotoxin shock. Life Sci. (1995) 57:307–313.
   Web of Science ®Google Scholar
• SANDERSON PE: Small, noncovalent serine proteaseinhibitors. Med. Res. Rev. (1999) 19:179–197.
   PubMed Web of Science ®Google Scholar
• MAY RD, HAWKESWOOD E, POWLING MJ: Superior efficacy of low molecular weight thrombin inhibitors in a novel in vitro model of clot bound thrombin. Blood (1994) 84:273a.
   Web of Science ®Google Scholar
• CLOSE P, BICHLER J, KERRY R et al.: Weak allergenicity ofrecombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group). Coron. Artery Dis. (1994) 5:943–949.
   PubMed Web of Science ®Google Scholar
• GUSTAFSSON D, ANTONSSON T, BYLUND R eta].: Effectsof melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemost. (1998) 79:110–118.
   Google Scholar
• •A preclinical study characterising melagatran.
   Google Scholar
• ELG M, GUSTAFSSON D, CARLSSON S: Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb. Res. (1999) 94:187–197.
   PubMed Web of Science ®Google Scholar
• •Thrombin inhibitors affecting only one enzyme in the coagulation cascade seem preferable.
   Google Scholar
• ERIKSSON BI, CARLSSON S, HALVARSSON M, RISBERG B,MATTSSON C: Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. Thromb. Haemost. (1997) 78:1404–1407.
   PubMed Web of Science ®Google Scholar
• ELG M, GUSTAFSSON D, DEINUM J: The importance ofenzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb. Haemost. (1997) 78:1286–1292.
   PubMed Web of Science ®Google Scholar
• MEHTA JL, CHEN L, NICHOLS WW, MATTSSON C, GUSTAFSSON D, SALDEEN TG: Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J. Cardiovasc. Pharmacol. (1998) 31:345–351.
   PubMed Web of Science ®Google Scholar
• •Oral melagatran prevents/delays the formation of experi-mental thrombi.
   Google Scholar
• MATTSSON C, BJORKMAN J-A, ULVINGE J-C: Melagatran, hirudin and heparin as adjuncts to tissue-type plasmi-nogen activator in a canine model of coronary artery thrombosis. Fibrinol Proteol. (1997) 11:121–128.
   Google Scholar
• •Melagatran enhances the fibrinolytic effect of plasminogen activator in experimental arterial thrombosis.
   Google Scholar
• ANDREOTTI F: The TIMI 9b and GUSTO fib Trials andthe 'Thrombin Hypothesis'. J. Thromb. Thrombol. (1997) 4:311–313.
   PubMedGoogle Scholar
• ERIKSSON BI, EKMAN S, KALEBO P, ZACHRISSON B, BACH D, CLOSE P: Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibi-tion with recombinant hirudin, CGP 39393. Lancet (1996) 347:635–639.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BI, ARFWIDSSON AC, ELVANDER SAREYKO Cet al.: Subcutaneous and oral direct thrombin inhibi-tors for prophylaxis of deep venous thrombosis and pulmonary embolism after total hip and knee replace-ment. Blood (1999) 94 (Suppl. 10 Pt. 1):589a.
   Google Scholar
• TAPPARELLI C, METTERNICH R, EHRHARDT C, COOK NS:Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol. Sci. (1993) 14:366–376.
   PubMed Web of Science ®Google Scholar
• ERIKSSON M, LARSSON A, SALDEEN T, MATTSSON C: Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemody-namic and renal dysfunctions in the pig. Thromb. Haemost. (1998) 80:1022–1026.
   PubMed Web of Science ®Google Scholar
• •Melagatran in experimental septic shock.
   Google Scholar
• ERIKSSON M, SALDEEN T, MATTSSON C, LARSSON A: Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics and platelet count in endotoxaemic pigs. Acta Anaesthesiol. Scand. (2000) 44:24–31.
   PubMed Web of Science ®Google Scholar
• •Melagatran in experimental septic shock.
   Google Scholar
• CLARK CA, HARMAN EM: Hemodynamic monitoring: Pulmonary artery catheters. In: Critical Care. Civetta JM, Taylor RW, Kirby RR (Eds.) J B Lippincott Co., Philadelphia, USA (1988)293–302.
   Google Scholar
• ERIKSSON M, NELSON D, NORDGREN A, LARSSON A: Increased platelet microvesicle formation is associ-ated with mortality in a porcine model of endotoxemia. Acta Anaesthesiol. Scand. (1998) 42:551–557.
   PubMed Web of Science ®Google Scholar
• GONDA Y, HIRATA S, SAITOH K et al.: Antithromboticeffect of recombinant human soluble thrombo-modulin on endotoxin-induced disseminated intravascular coagulation in rats. Thromb. Res. (1993) 71:325–335.
   PubMed Web of Science ®Google Scholar
• ERIKSSON M, MODIG J, LARSSON A, ROLLMAN O, ERIKSSON O: Retinyl palmitate injections reduce serum levels and effects of endotoxin on systemic haemodynamics and oxygen transport in the pig. Acta Anaesthesiol. Scand. (1998) 42:406–413.
   PubMed Web of Science ®Google Scholar
• BUCHA E, NOWAK G: The Ecarin Coagulation Time (ECT) the first specific method suited for quick determination of thrombin inhibitors in whole blood, plasma and body fluids. Int. Anglo]. (1995) 14:174.
   Google Scholar
• MODIG J, BORG T: Biochemical markers in a porcinemodel of adult respiratory distress syndrome induced by endotoxemia. Resuscitation (1986) 14:225–236.
   PubMed Web of Science ®Google Scholar
• STEMBERGER A, STRASSER F, HANDELSHAUSER B, TEMPEL G, BLUMEL G: Detection of plasma endotoxin with a limulus amoebocyte lysate (LAL)-chromogenic substrate assay. Acta Chir. Scand. Suppl. (1982) 509:49–53.
   PubMedGoogle Scholar
• DUBOSCQ C, QUINTANA I, BASSILOTTA E et al: Plasmi-nogen: an important hemostatic parameter in septic patients. Thromb. Haemost. (1997) 77:1090–1095.
   PubMed Web of Science ®Google Scholar
• HARDAWAY RM, WILLIAMS CH, SUN Y: A new approach to the treatment of experimental septic shock. J. Surg. Res. (1996) 61:311–316.
   PubMed Web of Science ®Google Scholar
• SMITH OP, WHITE B, VAUGHAN D eta].: Use of protein-C concentrate, heparin and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet (1997) 350:1590–1593.
   Google Scholar
• •Protein C may have a beneficial role in meningococcal Purpura fulminans.
   Google Scholar
• NADEL S, DE MUNTER C, BRITTO J, HABIBI P, LEVIN M:Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Grit. Care Med. (1998) 26:971–972.
   PubMed Web of Science ®Google Scholar
• ZENZ W, BODO Z, ZOBEL G, FANCONI S, RETTEN-BACHER A: Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Grit. Care Med. (1998) 26:969–971.
   PubMed Web of Science ®Google Scholar